R R

What Is Rivastigmine?

Rivastigmine is a prescription cholinesterase inhibitor used to treat certain forms of dementia. It is associated with the brand name Exelon and is available as oral capsules, oral solution, and transdermal patches. Rivastigmine is approved for dementia associated with Alzheimer's disease and Parkinson's disease, with disease severity requirements varying by formulation. It increases the availability of acetylcholine, a neurotransmitter involved in memory and cognitive function. Rivastigmine may improve or stabilize certain symptoms for a period but does not stop the underlying neurodegenerative disease. Doses require gradual adjustment to reduce gastrointestinal and other adverse reactions.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Rivastigmine?

Rivastigmine is a prescription cholinesterase inhibitor used to treat certain forms of dementia. It is associated with the brand name Exelon and is available as oral capsules, oral solution, and transdermal patches. Rivastigmine is approved for dementia associated with Alzheimer's disease and Parkinson's disease, with disease severity requirements varying by formulation. It increases the availability of acetylcholine, a neurotransmitter involved in memory and cognitive function. Rivastigmine may improve or stabilize certain symptoms for a period but does not stop the underlying neurodegenerative disease. Doses require gradual adjustment to reduce gastrointestinal and other adverse reactions.

read more about rivastigmine ...

Copy this HTML:

Copy HTML Copied!

How Does Rivastigmine Work?

Rivastigmine inhibits acetylcholinesterase and butyrylcholinesterase, enzymes that break down acetylcholine in the nervous system. Acetylcholine plays a role in memory, attention, learning, and other cognitive functions. Patients with Alzheimer's disease and Parkinson's disease dementia can experience reduced cholinergic signaling as neurological damage progresses. By slowing acetylcholine breakdown, rivastigmine increases its availability at nerve connections. This can improve certain cognitive or functional symptoms, although benefits vary among patients. Rivastigmine does not replace damaged neurons or prevent continued disease progression. Increased cholinergic activity also contributes to nausea, vomiting, slower heart rate, and other adverse effects.

What Types of Dementia Does Rivastigmine Treat?

Rivastigmine oral formulations are approved for mild to moderate dementia associated with Alzheimer's disease and mild to moderate dementia associated with Parkinson's disease. Rivastigmine transdermal patches are approved for mild, moderate, and severe Alzheimer's dementia and mild to moderate Parkinson's disease dementia. Alzheimer's disease can cause progressive difficulties with memory, language, reasoning, and daily activities. Parkinson's disease dementia involves cognitive decline in patients with established Parkinson's disease. Rivastigmine is intended for diagnosed dementia rather than ordinary age-related forgetfulness. Clinicians assess cognitive symptoms, functional abilities, heart rate, body weight, and medication interactions before prescribing it.

How Should Rivastigmine Be Taken or Applied?

Rivastigmine capsules and oral solution are generally taken twice daily with morning and evening meals. Oral treatment begins at 1.5 mg twice daily and may be increased gradually to a maximum of 6 mg twice daily when tolerated. Rivastigmine patches begin at 4.6 mg per 24 hours, with increases to 9.5 mg and, when appropriate, 13.3 mg per 24 hours after at least four weeks at each dose. Apply one patch to clean, dry, intact skin and replace it every 24 hours, removing the previous patch first. After an interruption longer than three days, treatment must restart at the lowest recommended dose and be retitrated.

What Are the Side Effects and Warnings of Rivastigmine?

Common adverse effects include nausea, vomiting, diarrhea, reduced appetite, weight loss, dizziness, and headache. Rivastigmine can cause clinically significant dehydration and slow heart rate, potentially leading to fainting. Patients with stomach ulcers, cardiac conduction disorders, or low body weight may require closer monitoring. Application-site reactions and allergic contact dermatitis can occur with patches. Serious medication errors have resulted from applying multiple patches simultaneously or failing to remove an old patch. Excessive cholinergic activity can cause severe vomiting, sweating, muscle weakness, and breathing problems. Persistent vomiting, fainting, severe skin reactions, or suspected patch overdose requires immediate medical assessment.

Common Questions About Rivastigmine

Is rivastigmine the same as Exelon?

Yes. Exelon is a brand name associated with rivastigmine, a cholinesterase inhibitor used for Alzheimer's and Parkinson's disease dementia.

Can rivastigmine treat severe Alzheimer's disease?

Rivastigmine transdermal patches are approved for severe Alzheimer's dementia. Oral rivastigmine formulations are approved for mild to moderate Alzheimer's dementia.

How often should rivastigmine patches be changed?

Apply one new patch every 24 hours and remove the previous patch first. Wearing multiple patches can cause serious overdose.

What happens if rivastigmine is stopped for several days?

After an interruption longer than three days, rivastigmine must be restarted at its lowest recommended dose and increased gradually under medical supervision.

References

DailyMed - EXELON (rivastigmine) transdermal patch. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07c12e14-bbd5-4ec8-84e4-fbe7b5ba10e0. Date Accessed November 4, 2026.

Rivastigmine. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548942/. Date Accessed November 4, 2026.

Rivastigmine. MedlinePlus. https://medlineplus.gov/druginfo/meds/a602009.html. Date Accessed November 4, 2026.

Rivastigmine. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Rivastigmine. Date Accessed November 4, 2026.

Rivastigmine Transdermal Patch. MedlinePlus. https://medlineplus.gov/druginfo/meds/a607078.html. Date Accessed November 4, 2026.